Table 4.
Clinical efficacy of approved anti-HIV regimens in phase 2/3 clinical trials.
| Brand name | Prior treatment | Arm | Efficacya | P-value | Study (phase) | Ref. |
|---|---|---|---|---|---|---|
| Complera® | Treatment-naive | RPV + TDF + FTC | 83% (287/346) | 0.17 | NCT00540449 (phase 3) | 195 |
| EFV + TDF + FTC | 83% (285/344) | |||||
| Treatment-naive | RPV + TDF + FTC | 86% (338/394) | 0.12 | NCT01309243 (phase 3b) | 196 | |
| EFV + TDF + FTC | 82% (320/394) | |||||
| Juluca® | Virologically suppressed | RPV + DTG | 95% (486/513) | 0.90 |
NCT02429791 NCT02422797 (phase 3) |
88 |
| ART regimen | 95% (485/511) | |||||
| Cabenuva® | Virologically suppressed | RPV + CAB (monthly) | 91% (105/115) | 0.82 | NCT02120352 (phase 2b) | 197 |
| RPV + CAB (bimonthly) | 92% (106/115) | |||||
| ABC + 3TC + CAB | 89% (50/56) | |||||
| Virologically suppressed | RPV + CAB (monthly) | 94% (265/283) | 0.87 | NCT02938520 (phase 3) | 198 | |
| ABC + 3TC + DTG | 93% (264/283) | |||||
| Virologically suppressed | RPV + CAB (monthly) | 93% (285/308) | 0.13 | NCT02951052 (phase 3) | 199 | |
| ART regimen | 96% (294/308) | |||||
| Virologically suppressed | RPV + CAB (monthly) | 93% (489/523) | 0.61 | NCT03299049 (phase 3b) | 200 | |
| RPV + CAB (bimonthly) | 94% (492/522) | |||||
| Delstrigo™ | Treatment-naive | DOR + TDF + 3TC | 84% (307/364) | 0.24 | NCT02403674 (phase 3) | 201 |
| EFV + TDF + FTC | 81% (294/364) | |||||
| Treatment-naive | DOR + TDF + 3TC | 83% (278/333) | 0.34 | NCT02275780 (phase 3) | 202 | |
| DOR + ABC + 3TC | 86% (43/50) | |||||
| PI-based regimen | 80% (306/383) | |||||
| Virologically suppressed | DOR + TDF + 3TC | 91% (406/447) | 0.12 | NCT02397096 (phase 3) | 203 | |
| Baseline regimen | 95% (211/223) |
a
Clinical efficacy was defined by HIV-1 RNA <50 copies/mL at Week 48.